Tier 2 — strong

Effectiveness of the integration of quercetin, turmeric, and N-acetylcysteine in reducing inflammation and pain associated with endometriosis. In-vitro and in-vivo studies

Mario Fadin, Maria C Nicoletti, Marzia Pellizzato, Manuela Accardi, Maria G Baietti, Andrea Fratter
Minerva ginecologica 2020 72(5):285-291

Bibliography

PubMed
PMID 32921020
DOI
10.23736/S0026-4784.20.04615-8
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignUncontrolled clinical endometriosis study with supporting laboratory work
ModelHuman intervention research
Sample33 women
InterventionQuercetin 200 mg, curcuma extract 210 mg, and acetylcysteine 150 mg/day
Duration2 months
EndpointsSymptoms and quality of life

What the study showed, in plain terms

Published in 2020, this source examined hormones and reproductive health. Design: Uncontrolled clinical endometriosis study with supporting laboratory work. Sample/model: 33 women. The exposure or intervention was Quercetin 200 mg, curcuma extract 210 mg, and acetylcysteine 150 mg/day. Follow-up or treatment period: 2 months.

Pain symptoms and reported NSAID use decreased from baseline.

No placebo comparison and multiple active ingredients. Effects cannot be assigned to quercetin or separated from expectations, natural variation, and concurrent care.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Benefits: What Human Studies Actually Show. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Pain symptoms and reported NSAID use decreased from baseline.
  • The recorded outcome domains were Symptoms and quality of life.
  • The result applies to the tested exposure: Quercetin 200 mg, curcuma extract 210 mg, and acetylcysteine 150 mg/day; 2 months.

What this study can and cannot tell us

  • No placebo comparison and multiple active ingredients. Effects cannot be assigned to quercetin or separated from expectations, natural variation, and concurrent care.
  • Without a sufficiently blinded concurrent control, time effects, expectations, co-interventions and regression toward the mean can explain part of an apparent improvement.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology